4.6 Article

The apoptotic pathway contributing to the deletion of naive CD8 T cells during the induction of peripheral tolerance to a cross-presented self-antigen

期刊

JOURNAL OF IMMUNOLOGY
卷 180, 期 8, 页码 5275-5282

出版社

AMER ASSOC IMMUNOLOGISTS
DOI: 10.4049/jimmunol.180.8.5275

关键词

-

资金

  1. NIAID NIH HHS [T32 AI007606, T32 AI07606] Funding Source: Medline
  2. NIDDK NIH HHS [R01 DK050824, R01 DK50824] Funding Source: Medline

向作者/读者索取更多资源

The maintenance of T cell tolerance in the periphery proceeds through several mechanisms, including anergy, immuno-regulation, and deletion via apoptosis. We examined the mechanism underlying the induction of CD8 T cell peripheral tolerance to a self-Ag expressed on pancreatic islet beta-cells. Following adoptive transfer, Ag-specific clone 4 T cells underwent deletion independently of extrinsic death receptors, including Fas, TNFR1, or TNFR2. Additional experiments revealed that the induction of clone 4 T cell apoptosis during peripheral tolerance occurred via an intrinsic death pathway that could be inhibited by overexpression of Bcl-2 or targeted deletion of the proapoptotic molecule, Bim, thereby resulting in accumulation of activated clone 4 T cells. Over-expression of Bcl-2 in clone 4 T cells promoted the development of effector function and insulitis whereas Bim(-/-) clone 4 cells were not autoaggressive. Examination of the upstream molecular mechanisms contributing to clone 4 T cell apoptosis revealed that it proceeded in a p53, E2F1, and E2F2-independent manner. Taken together, these data reveal that initiation of clone 4 T cell apoptosis during the induction of peripheral tolerance to a cross-presented self-Ag occurs through a Bcl-2-sensitive and at least partially Bim-dependent mechanism.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Biochemical Research Methods

Implementation and Validation of an Automated Flow Cytometry Analysis Pipeline for Human Immune Profiling

Valerie K. Conrad, Christopher J. Dubay, Mehrnoush Malek, Ryan R. Brinkman, Yoshinobu Koguchi, William L. Redmond

CYTOMETRY PART A (2019)

Article Oncology

A Phase Ib Study of Preoperative, Locoregional IRX-2 Cytokine Immunotherapy to Prime Immune Responses in Patients with Early-Stage Breast Cancer

David B. Page, Joanna Pucilowska, Katherine G. Sanchez, Valerie K. Conrad, Alison K. Conlin, Anupama K. Acheson, Kelly S. Perlewitz, James H. Imatani, Shaghayegh Aliabadi-Wahle, Nicole Moxon, Staci L. Mellinger, Amanda Y. Seino, Martiza Martel, Yaping Wu, Zhaoyu Sun, William L. Redmond, Venkatesh Rajamanickam, Dottie Waddell, Deborah Laxague, Monil Shah, Shu-Ching Chang, Walter J. Urba

CLINICAL CANCER RESEARCH (2020)

Article Oncology

NKTR-214 immunotherapy synergizes with radiotherapy to stimulate systemic CD8+T cell responses capable of curing multi-focal cancer

Joshua M. Walker, Annah S. Rolig, Deborah H. Charych, Ute Hoch, Melissa J. Kasiewicz, Daniel C. Rose, Michael J. McNamara, Ian F. Hilgart-Martiszus, William L. Redmond

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)

Article Oncology

A phase II single-arm study of pembrolizumab with enzalutamide in men with metastatic castration-resistant prostate cancer progressing on enzalutamide alone

Julie N. Graff, Tomasz M. Beer, Joshi J. Alumkal, Rachel E. Slottke, William L. Redmond, George Thomas, Reid F. Thompson, Mary A. Wood, Yoshinobu Koguchi, Yiyi Chen, Emile Latour, Raymond C. Bergan, Charles G. Drake, Amy E. Moran

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)

Article Immunology

Intracellular Galectin-3 Is Essential for OX40-Mediated Memory CD8+ T Cell Development

Mohammad Farhad Amani, Annah S. Rolig, William L. Redmond

JOURNAL OF IMMUNOLOGY (2020)

Article Multidisciplinary Sciences

Developing an enhanced 7-color multiplex IHC protocol to dissect immune infiltration in human cancers

Zhaoyu Sun, Richard Nyberg, Yaping Wu, Brady Bernard, William L. Redmond

Summary: The TSA Opal multiplex immunohistochemistry protocol has been used to characterize immune infiltration in human cancers. Two improved protocols were developed for a 7-color panel with 6 biomarkers, showing that antigen retrieval method is crucial for staining intensity. The study demonstrated the importance of proper antigen retrieval method in multiplex immunohistochemistry and its impact on individual biomarker staining intensity.

PLOS ONE (2021)

Article Oncology

Enhancing the Generation of Eomeshi CD8+ T Cells Augments the Efficacy of OX40-and CTLA-4-Targeted Immunotherapy

Dana A. Emerson, Annah S. Rolig, William L. Redmond

Summary: The combination of CTLA-4 blockade and OX40-specific monoclonal antibody has been shown to enhance antitumor immunity by upregulating Eomes expression in CD8(+) T cells. Further modulation of Eomes expression through ITK signaling with ibrutinib can lead to enhanced tumor regression and improved survival, making the combination therapy a potential triple therapy option for improving immunotherapy efficacy.

CANCER IMMUNOLOGY RESEARCH (2021)

Article Immunology

Proautoimmune Allele of Tyrosine Phosphatase, PTPN22, Enhances Tumor Immunity

Robin C. Orozco, Kristi Marquardt, Kerri Mowen, Linda A. Sherman

Summary: The proautoimmune allele of PTPN22 promotes a strong antitumor response in innate and adaptive immune cells, leading to enhanced resistance to tumor growth in mice. This results in increased infiltration of CD8 T cells, CD4 T cells, and cDC1 cells in tumors from PEP-619WW mice, indicating superior control of tumors compared to wild type mice. Additionally, tumor-infiltrating cDC1 cells from PEP-619WW mice show decreased PD-L1 expression, further contributing to the antitumor immune response.

JOURNAL OF IMMUNOLOGY (2021)

Article Oncology

Trough levels of ipilimumab in serum as a potential biomarker of clinical outcomes for patients with advanced melanoma after treatment with ipilimumab

Yoshinobu Koguchi, Noriko Iwamoto, Takashi Shimada, Shu-Ching Chang, John Cha, Brendan D. Curti, Walter J. Urba, Brian D. Piening, William L. Redmond

Summary: Trough levels of ipilimumab may be a useful biomarker for long-term survival of patients with advanced melanoma, with associations with CXCL11 and sCD25 suggesting a baseline-driven E-R relationship, while associations with CRP and IL-6 levels indicate response-driven E-R relationship.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)

Article Oncology

Changes in T-cell subsets and clonal repertoire during chemoimmunotherapy with pembrolizumab and paclitaxel or capecitabine for metastatic triple-negative breast cancer

Brie Chun, Joanna Pucilowska, ShuChing Chang, Isaac Kim, Benjamin Nikitin, Yoshinobu Koguchi, William L. Redmond, Brady Bernard, Venkatesh Rajamanickam, Nathan Polaske, Paul A. Fields, Valerie Conrad, Mark Schmidt, Walter J. Urba, Alison K. Conlin, Heather L. McArthur, David B. Page

Summary: This study investigates the effects of pembrolizumab combined with paclitaxel or capecitabine on T-cell subsets in triple-negative breast cancer patients. The results show that these treatments result in similar lymphodepletions across peripheral T-cell subsets and do not alter T-cell clonal diversity. The findings contribute to our understanding of the impact of chemoimmunotherapy on the immune system.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)

Review Oncology

Current Clinical Trial Landscape of OX40 Agonists

Rashi Yadav, William L. Redmond

Summary: This review discusses the impact of OX40 agonists on T cell function and the therapeutic potential of OX40 agonists alone or in conjunction with ICB for patients with advanced malignancies.

CURRENT ONCOLOGY REPORTS (2022)

Article Oncology

Combining bempegaldesleukin (CD122-preferential IL-2 pathway agonist) and NKTR-262 (TLR7/8 agonist) improves systemic antitumor CD8+ T cell cytotoxicity over BEMPEG plus RT

Annah S. Rolig, Daniel C. Rose, Grace Helen McGee, Werner Rubas, Saul Kivimae, William L. Redmond

Summary: This study aims to evaluate whether intratumoral NKTR-262 combined with systemic BEMPEG treatment can improve tumor-specific immunity and survival. The results showed that BEMPEG+NKTR-262 significantly improved survival and inhibited tumor growth by expanding activated CD8(+) T cells and enhancing cytolytic function.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)

Article Immunology

A Novel Class of On-Treatment Cancer Immunotherapy Biomarker: Trough Levels of Antibody Therapeutics in Peripheral Blood

Yoshinobu Koguchi, William L. Redmond

Summary: While immune checkpoint blockade has revolutionized cancer treatment, the majority of patients do not benefit from it. Various efforts have been made to interrogate the immune system using different biospecimens, technologies, and disciplines, but consistent biomarkers of response have remained elusive. Pharmacokinetics studies, however, provide critical information and may reveal useful biomarkers.

IMMUNOLOGICAL INVESTIGATIONS (2022)

Article Biochemical Research Methods

Characterization of murine lymphocyte activation and exhaustion markers by a 14-color flow cytometry panel

Daniel C. Rose, Annah S. Rolig, William L. Redmond

Summary: This article describes a flow cytometry panel specifically designed to assess the expression of activation and exhaustion markers in expanding lymphocyte populations in tumor-bearing mice. It enables the assessment of multiple functional states and immune checkpoint markers across various immune cell subsets in murine whole blood, lymph nodes, and tumor.

BIOANALYSIS (2023)

Article Oncology

Galectin-3 inhibition with belapectin combined with anti-OX40 therapy reprograms the tumor microenvironment to favor anti-tumor immunity

Elizabeth R. Sturgill, Annah S. Rolig, Stefanie N. Linch, Courtney Mick, Melissa J. Kasiewicz, Zhaoyu Sun, Peter G. Traber, Harold Shlevin, William L. Redmond

Summary: Combining Gal-3 inhibition with aOX40 therapy promotes tumor regression and increases survival by reducing M-MDSC-mediated immune suppression, enhancing CD8(+) T cell recruitment, leading to improved tumor regression and survival.

ONCOIMMUNOLOGY (2021)

暂无数据